Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives

Filippo Pagani, Maurizio Colecchia, Pierangela Sepe, Giulia Apollonio, Melanie Claps, Elena Verzoni, Filippo de Braud, Giuseppe Procopio

Research output: Contribution to journalReview articlepeer-review


Collecting ducts carcinoma (CDC) is a rare and aggressive histological subtype of renal cancer accounting for only 1% of renal tumors. Usually patients present in bad clinical conditions due to a symptomatic disease with synchronous metastasis. Due to the rarity of CDC, data from prospective trials evaluating the best treatment for these patients are limited. The prognosis is poor with a median overall survival of around 11 months for patients with metastatic disease. The best treatment option today is considered a doublet chemotherapy with platinum salt plus gemcitabine as a result from a prospective phase II trial, but survival outcomes remain unsatisfactory. The interest in the in-depth understanding the biology of this orphan disease is growing, leading to find potential new biological-driven treatment approaches. Here we review the up-to-date literature evidences to address the best management of this rare and unfavorable clinical condition.

Original languageEnglish
Article number101891
JournalCancer Treatment Reviews
Publication statusPublished - Sep 2019


  • Bellini disease
  • Chemotherapy
  • Collecting ducts carcinoma
  • Immunotherapy
  • Renal cell carcinoma
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives'. Together they form a unique fingerprint.

Cite this